Sarcomeal oral supplement in treating diabetic sarcopenia
- Conditions
- Diabetic sarcopenia.Muscle wasting and atrophy, not elsewhere classifiedM62.5
- Registration Number
- IRCT20230831059311N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
At least a history of 6 months of type 2 diabetes confirmed by a specialist doctor
Diagnosis of sarcopenia according to the criteria mentioned in the study method
Signing a written consent to participate in the study
Not using other supplements
Absence of severe hepatic or renal disorder
Absence of cancer
Existence of musculoskeletal disorders (back pain, knee pain, etc.) that lead to impaired walking
The existence of comorbid orthopedic and neurological problems such as stroke, cerebral palsy, poliomyelitis, rheumatoid arthritis, and prosthesis
The patient's unwillingness to cooperate
Occurrence of any unforeseen problems in patients
Not using more than 10% of supplements given in each follow-up
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.